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Abstract
Background Overexpression of the HER2 proto-oncogene in
human cancer cells has been associated with a poor prognosis,
and survival improves with therapy targeting the HER2 gene.
Animal studies and protein modeling suggest that the Ile655Val
polymorphism located in the transmembrane domain of the
HER2 protein might influence breast cancer development by
altering the efficiency of homodimerization.
Methods To investigate this genetic polymorphism, incident
cases of invasive breast cancer (N = 1,094) and population
controls of a similar age (N = 976) were interviewed during
2001 to 2003 regarding their risk factors for breast cancer. By
using DNA collected from buccal samples mailed by the
participants, the HER2 Ile655Val polymorphism was evaluated
with the Applied Biosystems allelic discrimination assay. Odds
ratios (ORs) and 95% confidence intervals (95% CIs) were
estimated by logistic regression adjusted for numerous breast
cancer risk factors. Analysis was restricted to women with self-
reported European descent.
Results Prevalence of the Val/Val genotype was 5.6% in cases
and 7.1% in controls. In comparison with the Ile/Ile genotype,
the Ile/Val genotype was not significantly associated with breast
cancer risk (OR 0.97, 95% CI 0.79 to 1.18), whereas the Val/
Val genotype was associated with a reduced risk (OR 0.63,
95% CI 0.42 to 0.92). This inverse association seemed
strongest in older women (OR 0.51, 95% CI 0.29 to 0.89 for
women aged more than 55 years), women without a family
history of breast cancer (OR 0.54, 95% CI 0.35 to 0.84),
postmenopausal women with greater body mass index (OR
0.43, 95% CI 0.20 to 0.91 for a body mass index of 25.3 kg/m2
or more), and cases diagnosed with non-localized breast cancer
(OR 0.49, 95% CI 0.26 to 0.90).
Conclusion Although results from our population-based case-
control study show an inverse association between the HER2
Ile655Val polymorphism and risk of invasive breast cancer, most
other studies of this single-nucleotide polymorphism suggest an
overall null association. Any further study of this polymorphism
should involve sample populations with complete risk factor
information and sufficient power to evaluate gene-environment
interactions between the HER2 polymorphism and factors such
as age and family history of breast cancer.
Introduction
The proto-oncogene human epidermal growth factor receptor
2 (HER2/neu, also called c-erbB-2) belongs to a family of
receptors involved in the tyrosine kinase-mediated regulation
of normal breast tissue growth and development [1]. HER2
amplification or overexpression is fairly common – present in
20 to 30% of human breast cancers – and is a significant pre-
dictor of response to therapy, prognosis, and overall survival
[1]. HER2 is also a target for therapy. Antibody therapy with
trastuzumab, which binds the extracellular portion of HER2,
has been associated with improved patient outcomes includ-
ing survival [2]. Because HER2 clearly has an important role in
prognosis after a diagnosis of breast cancer, the gene encod-
ing it is a natural target for investigation regarding polymor-
phisms that might indicate resistance or susceptibility for
breast cancer development.
CI = confidence interval; OR = odds ratio; SNP = single-nucleotide polymorphism.Breast Cancer Research    Vol 7 No 3    Nelson et al.
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One single-nucleotide polymorphism (SNP) at codon 655
indicates a guanine-to-adenine substitution (Ile655Val) in the
transmembrane domain-coding region of the HER2 gene [3].
This SNP has been evaluated in a variety of populations; stud-
ies show that the prevalence of the Val/Val genotype ranges
from 3% to 7% in control women [4-6], although this genotype
may be less common or unobserved in people with Asian or
African descent [7-9].
Epidemiologic studies of the association between the
Ile655Val polymorphism and breast cancer risk have generally
shown null associations, with risk estimates below unity
[4,5,10,11] and above unity [6,8,12-14]. Subgroup analysis in
several studies suggested that, among women who were
younger [7,8,14], physically inactive [7], had greater body
mass [7], or had a positive family history of breast cancer [6,8],
the Val/Val genotype was associated with an increased risk of
breast cancer in comparison with the Ile/Ile genotype. Further
study of this SNP has been supported because of the concern
that subgroups of identifiable women might be especially sus-
ceptible to breast cancer [6,10]. In the present study we eval-
uated the association between the HER2  Ile655Val
polymorphism and breast cancer risk in a population-based
case-control study of midwestern United States women.
Materials and methods
Study subjects
As part of a continuing epidemiologic study, we recruited pop-
ulation-based cases of incident invasive breast cancer as well
as community controls across Wisconsin in accordance with
a protocol approved by the University of Wisconsin Health
Sciences Human Subjects Committee. Invasive breast cancer
cases (excluding carcinoma in situ) aged 20 to 69 years were
identified though the Wisconsin statewide tumor registry.
Controls were randomly sampled from driver's license files
(ages 20 to 64 years) and Medicare beneficiary lists (ages 65
to 69 years); controls were frequency-matched in 5-year inter-
vals to have a similar age distribution to that of the cases. All
participants were required to have an available telephone
number, and controls who self-reported a personal history of
breast cancer were not eligible. Before April 2003, when
changes in federal law affected the willingness of physicians
to acknowledge their care of our eligible participants, physi-
cians (identified on the tumor registry reports) were contacted
before case enrollment to obtain information that might con-
traindicate study participation, such as dementia. All cases
and controls were contacted by mail before receiving an inter-
viewer's call. The 35-minute structured telephone interview
elicited complete reproductive and menstrual histories, exoge-
nous hormone use, smoking history, recent alcohol use and
recreational physical activity, lifetime occupational and resi-
dential history, and exposure to indoor and outdoor chemicals.
Information regarding the women's personal and family history
of cancer was obtained at the end of the interview to maintain
interviewer blinding. During April 2001 to January 2004, 77%
of eligible cases (N = 1,884) and 70% of eligible controls (N
= 2,146) participated in the telephone interview. The major
reasons for nonparticipation were refusal (15% of cases, 23%
of controls), death before the interview (2% of cases, 1% of
controls), and inability to locate (3% of cases, 6% of controls).
Before April 2003, physicians refused participation for 2% of
cases.
At the conclusion of the telephone interview, all cases and
controls were asked to provide a mouthwash rinse. Those
agreeing were mailed a kit containing a 44 ml bottle of Scope
mouthwash, consent forms, prepaid return mailing supplies,
and other all materials needed for producing the sample. Dur-
ing April 2001 to January 2004, samples were obtained from
1,482 cases (79%) and 1,727 controls (81%). Genomic DNA
was extracted by using the Gentra Systems DNA extraction
reagents and protocol. DNA was resuspended in sterile water.
Samples contained an average yield of 29.3 µg of DNA.
Genotyping
The laboratory staff were blinded to the identity and disease
status of the subjects. Samples were genotyped for the HER2
Ile655Val polymorphism with the Applied Biosystems allelic
discrimination assay-by-design (no. 185078430). The primers
and labeled oligonucleotide probes for this reaction were as
follows: forward, 5'-CCTGACCCTGGCTTCCG-3' ; reverse,
5'-ACCAGCAGAATGCCAACCA-3' ; VIC probe (detects T),
5'-ACGTCCATCATCTC-3' ; FAM probe (detects C), 5'-
CCATCGTCTCTGCG-3'. Samples were cycled with condi-
tions recommended by ABI. Fluorescence was detected with
the ABI 7700 and genotypes were called manually with the
detection software for this instrument. Genotyping failed for
45 subjects (2%). For quality control, DNA from 79 subjects
who had submitted two independent samples were geno-
typed; 100% (79 of 79) had identical genotypes for the two
samples. HER2 genotype was obtained for the 1,098 invasive
breast cancer cases and 991 controls with European descent
who had mailed their mouthwash samples to study staff by 30
June 2003. Because of the small number of women with non-
European descent (46 cases, 55 controls) and the low preva-
lence of the HER2 Val/Val genotype in Asian and African pop-
ulations, these women were not genotyped.
Statistical analysis
Only exposure status before an assigned reference date was
used in this analysis. For cases, this was the date of breast
cancer diagnosis. For comparability, control subjects were
assigned a reference date corresponding to the average time
from diagnosis to interview for the case group (about 1 year).
The reference age was defined as the age at the reference
date. Menopausal status was defined as postmenopausal if
the subject reported natural menopause or bilateral oophorec-
tomy before the reference date. Women reporting hysterec-
tomy alone were classified as postmenopausal if their
reference age was greater than or equal to the 90th centile ofAvailable online http://breast-cancer-research.com/content/7/3/R357
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Table 1
Characteristics of invasive breast cancer cases and population controls, Wisconsin, 2001 to 2003
Characteristic Cases (N = 1,094) Controls (N = 976) OR† 95% CI†
n % n %*
Family history of breast cancer
Absent 855 78.2 829 85.3 1 (Reference)
Present 231 21.1 132 13.1 1.69 1.33–2.16
Unknown 8 0.7 15 1.7 0.44 0.18–1.05
Recent alcohol consumption
None 153 14.0 166 16.8 1 (Reference)
1 drink/week 424 38.8 418 42.5 1.10 0.84–1.45
2–6 drinks/week 385 35.2 270 28.2 1.57 1.19–2.09
7 or more drinks/week 132 12.1 122 12.4 1.23 0.87–1.74
Parity
0–1 262 23.9 217 23.4 1 (Reference)
2 392 35.8 275 29.7 1.22 0.95–1.55
3 253 23.1 209 21.3 0.99 0.76–1.30
4 or more 187 17.1 275 25.6 0.58 0.44–0.77
Menopausal status
Postmenopausal 597 54.6 592 55.1 1 (Reference)
Premenopausal 415 37.9 313 36.8 1.25 0.92–1.70
Unknown 82 7.5 71 8.1 1.06 0.71–1.58
Age at menopause (years)‡
<45 138 23.1 175 30.1 1 (Reference)
45–49 113 18.9 127 21.4 1.15 0.80–1.65
50–54 205 34.3 172 29.0 1.61 1.16–2.23
55+ 68 11.4 65 10.1 1.42 0.91–2.20
Unknown 73 12.2 53 9.4 1.76 1.14–2.77
Body mass index (kg/m2)‡
<22.6 129 21.6 135 23.1 1 (Reference)
22.6–25.2 144 24.1 136 22.8 1.18 0.82–1.69
25.3–28.9 166 27.8 161 26.8 1.09 0.77–1.54
29.0+ 153 25.6 156 26.6 0.97 0.69–1.38
Weight change since age 18 (kg)‡
Lost 5 or more 14 2.3 20 3.5 0.92 0.42–2.03
Lost 5 to gained 4 95 15.9 109 18.9 1 (Reference)
Gained 5 to 11 148 24.8 140 23.3 1.42 0.97–2.09
Gained 12 to 21 179 30.0 172 28.7 1.30 0.90–1.88
Gained 22 or more 154 25.8 143 24.3 1.32 0.91–1.93
HRT use‡
Never 184 30.8 233 37.9 1 (Reference)
Former 45 7.5 77 12.6 0.65 0.42–1.01
Current 368 61.6 282 49.4 1.49 1.14–1.95
Age at menarche (years)Breast Cancer Research    Vol 7 No 3    Nelson et al.
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age at natural menopause for the control group (54 years for
smokers and 56 years for nonsmokers). Menopausal status
was considered to be unknown for women with hysterectomy
without bilateral oophorectomy if their reference age was
between 42 and 54 years (or 56 years for nonsmokers).
Adjusted odds ratios (ORs) and 95% confidence intervals
(CIs) were obtained from multivariable conditional logistic
regression models stratified on age. Covariates for the models
were chosen by forward stepwise regression (Pentry = 0.20,
Premoval = 0.30). After forward stepwise regression had been
performed, covariates remaining in the model were: family his-
tory of breast cancer in a mother, daughter, or sister (yes, no,
unknown), recent alcohol consumption (four categories), par-
ity (four categories), menopausal status and age at meno-
pause (four categories of age at menopause, premenopausal,
unknown), hormone replacement therapy use (never, former,
current), age at menarche (five categories of age, plus
unknown), height at age 25 years (continuous), weight at age
18 years (continuous) and weight change since age 18 years
(five categories). Covariates that did not remain in the final
model included age at first birth, education, and income.
Women with unknown recent alcohol consumption, hormone
replacement therapy use, or height at age 25 years were not
included in the analysis (4 cases, 15 controls), so that 1,094
cases and 976 controls remained in the analysis. Interactions
with genotype in relation to breast cancer risk were evaluated
by including a cross-product term in the regression model and
measuring the change in the log-likelihood.
Results
Breast cancer cases were more likely than controls to report a
positive family history of breast cancer, to drink modest
amounts of alcohol, to have lower parity, to report menopause
at later ages, to have a younger age at menarche, and to report
taller adult height (Table 1). Cases in this HER2 analysis were
slightly less likely to have non-localized breast cancer at diag-
nosis; 32% of cases who contributed buccal samples that
were included in the HER2 analysis had regional or distant-
staged disease at diagnosis, whereas 37% of cases who
refused to contribute a sample had non-localized disease (N =
356, P = 0.07 by Fisher's exact test). Participants in this anal-
ysis were similar to nonparticipants in body mass index (P =
0.14 for cases, P = 0.29 for controls by t-test; N = 442 non-
participant controls) and family history of breast cancer (P =
0.27 for cases, P = 0.36 for controls by Fisher's exact test),
although control participants were somewhat older (55 versus
53 years, P = 0.02 by t-test) and more likely to have attended
college than nonparticipant controls (56% versus 50%, P =
0.05 by Fisher's exact test). Among cases, participants in this
analysis did not differ significantly from nonparticipants in age
(54 versus 53 years, P = 0.73) but were slightly more likely to
have attended college (57% versus 52%, P = 0.09).
The Ile allele frequency was similar for cases and controls
(cases 76.3%, 95% CI 74.5 to 78.1%; controls 74.7%, 95%
CI 72.8 to 76.6%), and the Val allele frequency was about
25% (cases 23.7%, 95% CI 21.9 to 25.5%; controls 25.3%,
95% CI 23.4 to 27.2%); 58.2% of cases and 56.5% of con-
trols were homozygous for the Ile allele, 36.2% of cases and
36.5% of controls were heterozygous, and 5.6% of cases and
7.1% of controls were homozygous for the Val allele (Table 2).
Both the case group (P = 0.96) and the control group (P =
0.28) were consistent with Hardy-Weinberg equilibrium.
After multivariable adjustment, the combined Ile/Val and Val/
Val genotypes were not significantly associated with a risk of
breast cancer relative to two copies of the Ile allele (OR 0.90,
95% CI 0.75 to 1.09; Table 2). The presence of two copies of
the Val allele was associated with a 37% reduced risk of
breast cancer compared with the Ile/Ile genotype (OR 0.63,
95% CI 0.42 to 0.92). Whereas this inverse association was
suggested for cases diagnosed with localized breast cancer
(OR 0.69, 95% CI 0.45 to 1.06), the OR was significantly
reduced for cases diagnosed with regional or distant metasta-
sis (OR 0.49, 95% CI 0.26 to 0.90).
< 12 228 20.8 176 18.1 1 (Reference)
12 282 25.8 253 26.4 0.83 0.64–1.09
13 297 27.1 244 24.4 0.94 0.72–1.23
14 183 16.7 172 17.6 0.81 0.61–1.10
15+ 98 9.0 119 12.4 0.63 0.45–0.89
Height at age 25 (m)
< 1.60 198 18.1 218 21.9 1 (Reference)
1.60–1.64 295 27.0 263 27.0 1.25 0.96–1.62
1.65–1.67 299 27.3 264 26.9 1.26 0.97–1.64
1.68+ 302 27.6 231 24.1 1.47 1.12–1.92
*Control percentages are age-adjusted to the distribution of cases; †logistic regression models conditional on age; ‡among postmenopausal 
women. CI, confidence interval; HRT, hormone replacement therapy; OR, odds ratio.
Table 1 (Continued)
Characteristics of invasive breast cancer cases and population controls, Wisconsin, 2001 to 2003Available online http://breast-cancer-research.com/content/7/3/R357
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Although no interactions between the HER2 polymorphism
and common risk factors were statistically significant, the
inverse association with breast cancer risk was strongest in
some subgroups (Table 3). In particular, ORs were signifi-
cantly reduced for women at older ages (more than 55 years),
without a family history of breast cancer, with older age at
menarche, currently using postmenopausal hormones, with
greater recent body mass index, and women with greater
weight gain since age 18 years. In addition, we could not find
evidence to support heterogeneity in the association between
the  HER2  Ile655Val polymorphism and breast cancer risk
according to recent physical activity (P  = 0.45), cigarette
smoking status (P = 0.66), adult height (P = 0.78), recent
alcohol intake (P = 0.83), parity (P = 0.81), or age at meno-
pause (P = 0.41) (data not shown).
Discussion
We observed a 40 to 50% decreased risk of breast cancer
associated with the inheritance of two HER2 valine alleles at
codon 655 for some subgroups of women, including women
older than 55 years of age and women without a family history
of breast cancer. Three other studies – one study of Asian
women [11] and two studies of women with European
descent [4,5,10] – have also reported decreased risk esti-
mates of breast cancer associated with inheritance of the
HER2 Val allele, although the estimates from these three other
studies were not statistically significant.
Our null results for younger women and women with a positive
family history of breast cancer do not concur with findings by
Montgomery and colleagues [14], which showed a threefold
increased risk among Australian women less than 40 years of
age. Wang-Gohrke and Chang-Claude [6] reported a twofold
increased risk among German Caucasians with a first-degree
family history of breast cancer. Similarly, Millikan and col-
leagues [8] reported a twofold increased risk of breast cancer
associated with the Val/Val or Val/Ile genotype (compared
with the Ile/Ile genotype) among women living in North Caro-
lina (United States) who were both less than 45 years of age
and reported a positive family history of breast cancer (OR 2.3,
95% CI 1.0 to 5.3). We were limited in our ability to examine
the HER2 polymorphism in younger women because of small
numbers. Only 4 controls and 12 cases in our study were 45
years of age or younger, reported a positive family history of
breast cancer, and also had the Val/Val or Val/Ile genotype
(OR 1.44, 95% CI 0.21 to 9.79, with Ile/Ile as the reference
category; data not shown).
The first study of the HER2 Ile655Val polymorphism in relation
to breast cancer risk found a very high risk (OR 14.1, 95% CI
1.8 to 113.4) of the Val/Val versus Ile/Ile genotype [7]. In that
study, the Val/Val genotype was detected in only 11 cases and
1 control. Risk estimates in subsequent studies have been
much more modest, ranging from 0.3 to 2.8, and our results
clearly fall within this (wide) range. Although risk estimates
Table 2
Risk of invasive breast cancer according to the HER2 Ile655Val polymorphism
Polymorphism Cases Controls OR* 95% CI* OR† 95% CI†
N % N %
All subjects
Ile/Ile 637 58.2 551 56.5 1 (Reference) 1 (Reference)
Ile/Val or Val/Val 457 41.8 425 43.5 0.92 0.76–1.10 0.90 0.75–1.09
Ile/Val 396 36.2 356 36.5 0.96 0.79–1.16 0.97 0.79–1.18
Val/Val 61 5.6 69 7.1 0.71 0.49–1.04 0.63 0.42–0.92
Localized disease‡
Ile/Ile 425 58.5 551 56.5 1 (Reference) 1 (Reference)
Ile/Val or Val/Val 301 41.5 425 43.5 0.91 0.74–1.12 0.90 0.73–1.12
Ile/Val 257 35.4 356 36.5 0.94 0.76–1.16 0.95 0.76–1.19
Val/Val 44 6.1 69 7.1 0.78 0.52–1.18 0.69 0.45–1.06
Regional or distant metastasis‡
Ile/Ile 195 57.5 551 56.5 1 (Reference) 1 (Reference)
Ile/Val or Val/Val 144 42.5 425 43.5 0.96 0.74–1.25 0.96 0.73–1.27
Ile/Val 128 37.8 356 36.5 1.03 0.79–1.36 1.08 0.81–1.44
Val/Val 16 4.7 69 7.1 0.60 0.34–1.09 0.49 0.26–0.90
*Logistic regression models conditional on age; †logistic regression models conditional on age and adjusted for family history of breast cancer, 
recent alcohol consumption, parity, menopausal status, age at menopause, hormone replacement therapy use, age at menarche, height at age 25 
years, weight at age 18 years, and weight change since age 18 years; ‡for cases at diagnosis. CI, confidence interval; OR, odds ratio.Breast Cancer Research    Vol 7 No 3    Nelson et al.
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have suggested both inverse and positive associations with
breast cancer risk, prevalence of the Val/Val genotype has
consistently been 3 to 8% in breast cancer cases and 3 to 7%
in controls in women with European descent. Allele frequen-
cies for case and control women corresponding to the Val/Val
genotype in our study are very similar to frequencies reported
in three other studies of white women in North Carolina, south-
east England, and Germany – ranging from 23% to 25% – and
slightly higher than frequencies for control women in two other
studies conducted in Australia and New York City (18.7% and
16%, respectively) [5,6,8,13,14].
Most studies of the HER2 Ile655Val polymorphism have used
a case-control design. Only one study population was a pro-
spective cohort [12]. Two other published reports used a kin-
cohort approach [15,16]. Using this novel design with a study
of 1,560 volunteers living in Washington DC and Israel, Rutter
and colleagues [16] reported that the HER2 valine allele might
be associated with a twofold to eightfold increased risk of
breast cancer. As with the Millikan study [8], these increased
risks were confined to younger women with a family history of
breast cancer.
Many studies of the HER2 Ile655Val polymorphism had insuf-
ficient power to evaluate interactions between the SNP and
subgroups according to risk factors such as age and family
history of breast cancer. Limited power is a common problem
in studies of genetic polymorphisms. Sample size for only one
other study was larger than the case and control enrollment in
our own study [8]. Prevalence of the Ile655Val polymorphism
clearly varies according to racial descent – it is rare or
unobserved in Asian and African populations [9,17] – further
limiting statistical power to evaluate the significance or rele-
vance of this SNP in different populations. Stratified analysis
of the HER2 Ile655Val genotype according to racial descent
is warranted.
Potential limitations might have influenced our findings.
Although participation in our study was excellent for a popula-
tion-based case-control study, certain subgroups might have
been under-represented because participation probably
Table 3
Risk of invasive breast cancer according to the HER2 Ile655Val polymorphism and common risk factors
Risk factor* HER2 polymorphism
Ile/Ile, cases/controls Val/Val, cases/controls Ile/Ile, OR†, 95% CI Val/Val, OR† (95% CI) P‡
Age (years) 0.29
<55 317/256 32/29 1 (reference) 0.78 (0.44–1.37)
55+ 320/295 29/40 1 (reference) 0.51 (0.29–0.89)
Family history of breast 
cancer
0.24
None 505/461 41/59 1 (reference) 0.54 (0.35–0.84)
Any 128/79 19/10 1 (reference) 0.92 (0.32–2.62)
Age at menarche (years) 0.14
<13 288/249 32/35 1 (reference) 0.88 (0.50–1.54)
≥ 13 346/297 29/33 1 (reference) 0.47 (0.27–0.84)
HRT use§ 0.19
Never/former 149/169 12/10 1 (reference) 1.24 (0.46–3.39)
Current 212/163 18/23 1 (reference) 0.46 (0.22–0.97)
Recent body mass index§ 0.07
<25.3 kg/m2 159/166 14/10 1 (reference) 1.01 (0.39–2.64)
≥ 25.3 kg/m2 196/163 14/25 1 (reference) 0.43 (0.20–0.91)
Weight change since age 
18 years (kg)§
0.12
Lost 5 to gained 11 142/148 14/11 1 (reference) 1.04 (0.41–2.67)
Gained 12 or more 204/164 14/22 1 (reference) 0.44 (0.20–0.98)
*Risk factor cut-points based on the approximate median values for the controls; †logistic regression models conditional on age and, as 
appropriate, adjusted for family history of breast cancer, recent alcohol consumption, parity, menopausal status, age at menopause, hormone 
replacement therapy use, age at menarche, height at age 25 years, weight at age 18 years, and weight change since age 18 years; ‡P interaction 
using the likelihood ratio test and assuming a multiplicative model (risk factors parameterized as dichotomous variables as shown in the table for 
purposes of the interaction tests); § postmenopausal women only. CI, confidence interval; HRT, hormone replacement therapy; OR, odds ratio.Available online http://breast-cancer-research.com/content/7/3/R357
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declines with increasing age, decreasing attained education,
and other factors. However, genetic inheritance with the
HER2 gene is probably not confounded with the variables that
might influence a woman's participation in our epidemiologic
study [18]. The distribution of the HER2 polymorphism in our
case and control groups was consistent with Hardy-Weinberg
equilibrium, which suggests that any genotyping errors were
not substantial. Duplicate genotyping of 79 samples was also
reassuring, achieving 100% concordance.
The mechanism through which this SNP might influence
breast cancer risk is unclear, although studies in transgenic
mice have demonstrated that activation or overexpression of
the HER2 gene leads to the development of mammary adeno-
carcinomas [19-21]. The transmembrane domain of the HER2
protein might be especially important, given the discovery of
an activating mutation in codon 664 in the rat [22-25]. In
humans, the Ile655Val amino acid substitution might alter the
formation of active HER2 dimers, which would then alter the
activity of the protein [26].
Conclusion
These data from our sample population of white women from
the midwestern United States suggest that the Val/Val geno-
type of the HER2 Ile655Val polymorphism is associated with
a reduced risk of breast cancer in comparison with the Ile/Ile
genotype for some women. Although the sample size in our
study was relatively large compared with other studies pub-
lished so far, the inconsistency of the findings across all stud-
ies argues against a strong relation with breast cancer risk.
Future large studies of the HER2 polymorphism might clarify
this putative gene-environment interaction. However, given the
promise of innovative and more comprehensive approaches to
genomic and proteomic studies of breast cancer risk, focusing
on this SNP without consideration of the role of other genes
and polymorphisms may not be warranted.
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